Introduction {#Sec1}
============

Many randomized clinical trials have demonstrated better efficacy of drug-eluting stents (DESs) in reducing restenosis and rate of repeat revascularization as compared with bare-metal stents (BMSs) \[[@CR1], [@CR2]\]. Although DESs were widespread and worked as a default device strategy in the majority of patients receiving percutaneous coronary intervention (PCI) for more than a decade, there was a considerable concern regarding late stent thrombosis (ST) \[[@CR3]--[@CR6]\]. Pathologic studies suggested that incomplete endothelialization of DESs was frequently observed even after 6 or 12 months after PCI \[[@CR7]--[@CR9]\], and clinically, most of thrombotic events tended to occur in the first 6--12 months after procedure and sometimes happened after the first year after DES implantation \[[@CR5], [@CR6]\]. As a result, prolonged use of dual antiplatelet therapy (DAPT) has become prevalent in clinical practice; however, careful balancing between ischemic benefits and bleeding risks according to the duration of DAPT has been an issue for several years \[[@CR10]--[@CR12]\].

On the basis of cumulative evidence, the current guidelines recommend that DAPT should be given either for 6--12 months (European guidelines \[[@CR13]\]) or for at least 12 months (U.S. guidelines \[[@CR14]\]) after DES implantation unless patients are at high risk for bleeding. However, these recommendations are largely based on registry data and randomized trials with a limited number of patients, and therefore the optimal duration of DAPT remains in question. Up to recently, several clinical studies have been performed to address questions about the optimal duration of DAPT in patients who have received DESs \[[@CR15]--[@CR21]\]. This article systemically reviews the current evidence from available clinical studies with the aim of helping physicians to make decisions on the optimal duration of DAPT for patients who are undergoing DES implantation.

Methods {#Sec2}
=======

PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched for randomized clinical trials and prospective or retrospective observational studies published between January 2002 and June 2014. Search terms were: "coronary artery disease", "clopidogrel", "drug-eluting stents", "dual antiplatelet therapy", and "percutaneous coronary intervention". Reference lists of review articles, meta-analyses, and original studies identified by the electronic searches were also checked to find other eligible studies for systemic reviews. In addition, conference proceedings/abstracts from the American Heart Association, American College of Cardiology, Transcatheter Cardiovascular Therapeutics, Society of Cardiovascular Angiography and Intervention, European Society of Cardiology, and Euro-PCR were searched. There was no language restriction for the search. We excluded studies with number of enrolled patients less than 500. The search process was fairly extensive, and efforts were made to obtain the longest reported follow-up data from a combination of sources.

Discussion {#Sec3}
==========

Longer Is Better {#Sec4}
----------------

There were several observational studies (not, randomized clinical trials) that supported relatively longer duration, more than 12 months of DAPT after DES implantation. Those were mostly from the early experiences of DESs which implies that these were data from the first-generation DES. Brief summary of each study design and primary results are summarized in Table [1](#Tab1){ref-type="table"} \[[@CR22]--[@CR26]\].Table 1Characteristics of the studies supporting longer duration of dual antiplatelet therapyStudyTotal *N* (DES)Stent typesClinical diagnosisDAPT durationEndpointFollow-up duration (months)FindingsSAACSBASKET-LATE (ISRCTN75663024) \[[@CR22]\]746 (545)BMS, DES42.3%57.7%7--18 mCardiac death or MI18Discontinuation of clopidogrel between 7 and 18 months after PCI: DES 4.9% vs. BMS 1.3%Duke registry \[[@CR23]\]4,666 (1,501)BMS, DES12 mCardiac death or MI24Discontinuation of clopidogrel at 12 months after PCI vs. continuation: 4.5% vs. 0% (*p* \< 0.001)Dutch registry \[[@CR24]\]1,303 (418)BMS, DES27.2%72.8%6--12 mST31Discontinuation of clopidogrel between 6 and 12 months after PCI: HR 5.87 (*p* = 0.004)Melbourne registry \[[@CR25]\]2,980 (1,669)BMS, DES38.5%61.5%\<6 vs. ≥12 mAll-cause death125.3% vs. 2.8%, *p* = 0.012SWEDEHEART registry (NCT01623700) \[[@CR26]\]42,268 (9,138)BMS, DES, no stent0.0%100.0%\>6 mAll-cause death, MI or CVA12Adjusted HR 0.75, *p* = 0.0155*ACS* acute coronary syndrome, *BMS* bare-metal stents, *CVA* cerebrovascular accident, *DAPT* dual antiplatelet therapy, *DES* drug-eluting stents, *HR* hazard ratio, *MI* myocardial infarction, *PCI* percutaneous coronary intervention, *SA* stable angina, *ST* stent thrombosis

A first safety concern with regard to DES implantation without long-term maintenance of clopidogrel was raised by data from the Basel Stent KostenEffektivitäts Trial---Late Thrombotic Events (BASKET-LATE) (ISRCTN75663024) \[[@CR22]\]. This study intended to define the incidence of late clinical events \[cardiac death or myocardial infarction (MI)\] and late ST in patients treated with the first-generation DESs versus BMSs after the discontinuation of clopidogrel and showed that more thrombotic events were found to occur 7--18 months after the procedure during the period with absence of DAPT, which were twice as frequent after DESs than BMSs. A subsequent, observational study from Duke registry highlighted the apparent benefits of extended clopidogrel use after first-generation DES implantation \[[@CR23]\]. In patients who continued clopidogrel for more than 6 or 12 months after DES placement, adjusted rates of death or MI at 24 months were significantly lower as compared with those in patients who did not continue clopidogrel (3.1% vs. 7.2%, *p* = 0.02). Patients in the BMS group had similar long-term mortality and rates of death/MI regardless of duration of clopidogrel at both landmark time points. In the Dutch registry, albeit in small numbers of DES patients, early discontinuation of clopidogrel, less than 12 months after the index PCI, was suggested as a strong predictor of ST \[hazard ratio (HR): 5.9, 95% confidence interval (CI) 1.7--19.8\] \[[@CR24]\]. Similarly, in the Melbourne Interventional Group registry, 12 months of DAPT resulted in reduced mortality than a shorter duration (≤6 months) of DAPT (2.8% vs. 5.3%, *p* = 0.012) \[[@CR25]\]. The SWEDEHEART(NCT01623700) registry data showed that \>6 months of DAPT compared with 6 months of DAPT among acute coronary syndrome (ACS) patients was associated with a lower risk of death, stroke, or re-infarction (HR 0.75, 95% CI 0.59--0.95) \[[@CR26]\]. Even in the subgroup analysis, with less than 6-month duration of DAPT, more than 3 months of DAPT lowered the risk of death, stroke, or re-infarction (HR 0.84, 95% CI 0.75--0.95) compared to less than 3 months of DAPT.

Shorter Is Better {#Sec5}
-----------------

By contrast, some observational studies and randomized trials suggested the safety and efficacy of shorter duration (less than 6--12 months) of DAPT would be comparable or better in safety outcomes compared to longer duration of DAPT among patients receiving DES implantation. Summary of these studies is shown in Table [2](#Tab2){ref-type="table"} \[[@CR4], [@CR5], [@CR16]--[@CR21], [@CR27]\].Table 2Characteristics of the studies supporting shorter duration of dual antiplatelet therapyStudyTotal *N* (DES)Stent typesClinical diagnosisDAPT durationEndpointFollow-up duration (months)FindingsSAACSRegistry data Airoldi et al. \[[@CR4]\]3,021SES, PES6 mST18Discontinuation of clopidogrel within 6 months vs. after 6 months of PCI: HR 13.74 (*p* \< 0.001) vs. HR 0.94 (*p* = 0.92) Munich registry \[[@CR5]\]6,816SES, PES65.0%35.0%6 mST48Discontinuation of clopidogrel within 6 months after PCI: significantly associated with ST (*p* \< 0.001) TYCOON \[[@CR27]\]897 (447)BMS, DES12 vs. 24 mST, cardiac death, TVR or MI483% vs. 0.4% of ST (*p* = 0.02)\
2% vs. 2% of cardiac death (*p* = 0.74)\
2% vs. 0.4% of MI (*p* = 0.30)Randomized trials ZEST-LATE (NCT00590174)/REAL-LATE (NCT00484926) \[[@CR17]\]2,701SES, PES, ZES37.6%62.4%12 vs. 24 mCardiac death or MI241.8% vs. 1.2% (*p* = 0.17) PRODIGY (NCT00611286) \[[@CR20]\]2,013 (1,497)BMS, PES, EES, ZES, no stent25.6%74.4%6 vs. 24 mAll-cause death, MI or CVA2410.0% vs. 10.1% (*p* = 0.91)\
Significantly high risk for bleeding in the 24-month group EXCELLENT (NCT00698607) \[[@CR16]\]1,443SES, EES48.4%51.6%6 vs. 12 mTVF (cardiac death, MI or TVR)124.8% vs. 4.3% (*p* = 0.001 for noninferiority)\
Diabetic patients in 6 month group: TVF was significantly frequent (HR 3.16, 95% CI 1.42--7.03, *p* = 0.005) RESET (NCT01145079) \[[@CR19]\]2,117E-ZES45.4%54.6%3 vs. 12 mCardiac death, MI, ST, TVR or bleeding124.7% vs. 4.7% (*p* \< 0.001 for noninferiority) OPTIMIZE (NCT01113372) \[[@CR21]\]3,119ZES68.2%31.9%3 vs. 12 mAll-cause death, MI, CVA or bleeding126.0% vs. 5.8% (*p* = 0.02 for noninferiority)*ACS* acute coronary syndrome, *BMS* bare-metal stents, *CVA* cerebrovascular accident, *DAPT* dual antiplatelet therapy, *DES* drug-eluting stents, *EES* everolimus-eluting stent, *HR* hazard ratio, *MI* myocardial infarction, *PCI* percutaneous coronary intervention, *PES* paclitaxel-eluting stent, *SA* stable angina, *SES* sirolimus-eluting stent, *ST* stent thrombosis, *TVR* target-vessel revascularization, *TVF* target-vessel failure, *ZES* zotarolimus-eluting stent

### Observational Studies {#Sec6}

Airoldi et al. \[[@CR4]\] suggested that discontinuation of thienopyridine therapy was the key determinant of ST occurrence within the first 6 months, but not longer than 6-month period. They suggested that a vulnerable period of ST associated with DAPT continuation would be within 6 months. Schulz et al. \[[@CR5]\] also demonstrated that the discontinuation of clopidogrel was a strong predictor for ST within the first 6 months but not thereafter after the first-generation DES implantation. The Two-Year Clopidogrel Need (TYCOON) study which is also based on the first-generation DES data, suggested that there was no long-term survival benefit in 24 months of DAPT compared to 12 months of DAPT, although early discontinuation of DAPT was the important predictor of ST (1% vs. 3%, *p* = 0.02) \[[@CR27]\].

### Randomized Trials {#Sec7}

Several randomized clinical trials demonstrated no reduction in death or MI with prolonged DAPT compared to standard or shorter duration of DAPT use. The first randomized trial, Evaluation of the Long-Term Safety after Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or Paclitaxel-Eluting Stent Implantation for Coronary Lesions---Late Coronary Arterial Thrombotic Events \[ZEST-LATE (NCT00590174)\]/Correlation of Clopidogrel Therapy Discontinuation in Real-World Patients Treated with Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events \[REAL-LATE (NCT00484926)\] randomized patients who were event free within 1 year after DES implantation to receive DAPT or aspirin alone \[[@CR17]\]. At 24 months, no difference was observed in the primary endpoint (composite of cardiac death or MI) or the risk for ST. However, majority of patients in these trials were treated with first-generation DES and the observed event rate was lower than expected, favoring a shorter duration of DAPT. Subsequently, in the DES-LATE (NCT01186146) study (extended study of ZEST-LATE/REAL-LATE), a total of 5,045 patients were randomized to either DAPT continuation or aspirin alone after 1 year of DES implantation \[[@CR18]\]. After 12 months, DAPT compared to aspirin alone showed no benefit in preventing ST (HR 1.59, 95% CI 0.61--4.09, *p* = 0.34), MI (HR 0.96, 95% CI 0.63--1.48, *p* = 0.86), or death (HR 0.71, 95% CI 0.45--1.10, *p* = 0.12). Incidence of major bleeding events between two groups was similar up to 24 months, but longer follow-up after 24 months revealed higher incidence of bleeding events in the DAPT continuation group (HR 0.67, 95% CI 0.47--0.95, *p* = 0.026).

The Prolonging Dual Antiplatelet Treatment after Grading Stent-induced Intimal Hyperplasia \[PRODIGY(NCT00611286)\] trial provided a major next step to answer this issue by including more diverse stent types (BMSs, first- and second-generation DESs) and by shortening the duration DAPT into 6 months \[[@CR20]\]. They randomized more than 2,000 patients to receive either 6 or 24 months of DAPT among patients who received a thin-strut BMS, a paclitaxel-eluting stent (PES), a zotarolimus-eluting stent (ZES), or an everolimus-eluting stent (EES) and therapy. There was no difference in the primary endpoints \[the composite of death from any cause, MI, or cerebrovascular accident (CVA)\] between the two groups. However, there was an excess of bleeding in patients assigned to 24 months of DAPT.

The Efficacy of Xience/Promus versus Cypher to Reduce Late Loss After Stenting \[EXCELLENT (NCT00698607)\] trial compared shorter duration of DAPT, 6 versus 12 months, following DES implantation \[[@CR16]\]. This study population predominantly received an EES (Xience or Promus, 74.8%) and rest of the patients received sirolimus-eluting stent (SES) (25.2%). The rate of target-vessel failure (TVF) (composite of cardiac death, MI, or ischemia-driven TVR) at 12 months was 4.8% in the 6-month DAPT group and 4.3% in the 12-month DAPT group (*p* = 0.001). Although ST tended to occur more frequently in the 6-month DAPT than 12-month DAPT (0.9% vs. 0.1%, HR 6.02; 95% CI 0.72--49.96; *p* = 0.10), the risk of death or MI did not differ between the two groups.

The REal Safety and Efficacy of 3-month DAPT following Endeavor zotarolimus-eluting stent implantation \[RESET (NCT01145079)\] trial compared the safety and efficacy of shorter duration (3 months) of DAPT and standard duration of 12 months of DAPT after Endeavor zotarolimus-eluting stent (E-ZES) implantation \[[@CR19]\]. Three-month DAPT was shown to be non-inferior to the standard 12-month therapy with respect to the primary endpoint (cardiac death, MI, ST, TVR, or bleeding).

Recently, the OPTIMIzed duration of clopidogrel therapy following treatment with the zotarolimus-eluting stent in real-world clinical practice \[OPTIMIZE (NCT01113372)\] trial, which included 3,119 patients with stable coronary artery disease or low-risk ACS treated with ZES to compare 3 versus 12 months of DAPT, suggested that 3 months of DAPT was non-inferior to 12 months of DAPT for reducing net adverse clinical and cerebral events (a composite of all-cause death, MI, stroke, or major bleeding), without significantly increasing the risk of ST \[[@CR21]\].

A meta-analysis of four randomized trials (REAL/ZEST-LATE, PRODIGY, EXCELLENT, RESET) was performed and the median DAPT duration was 16.8 months in the extended group versus 6.2 months in the control group \[[@CR28], [@CR29]\]. During follow-up, extended DAPT did not provide more clinical benefit \[no difference in mortality, odds ratio (OR) 1.15, 95% CI 0.85--1.54; MI, OR 0.95, 95% CI 0.66--1.36; and ST, OR 0.88; 95% CI 0.43--1.81\] as compared to shorter duration of DAPT; however, prolonged use of DAPT was associated with an increase of major bleeding (OR 2.64, 95% CI 1.31--5.30). Consistent findings were obtained in another meta-analysis, further including the OPTIMIZE trial \[[@CR30], [@CR31]\]. A total of 4,081 patients received DAPT for 3--6 months, and 4,076 patients were treated with DAPT for 12--24 months. There was no significant difference in the rate of the composite of cardiac death or MI between the short and prolonged DAPT groups (3.3% vs. 3.0%; OR 1.11, 95% CI 0.87--1.43, *p* = 0.41). But major bleeding was significantly higher in the group of patients treated with prolonged DAPT (0.29% vs. 0.71%, *p* = 0.01).

Therefore, current available randomized clinical trials and meta-analyses suggest that extension of the duration of DAPT after DES implantation might increase the risk of bleeding without reducing ischemic events. But, considering the limited sample size and the inclusion of mainly low-risk patients with low event rates in these trials, still the safety of short-term DAPT remains uncertain.

Ongoing Randomized Trials {#Sec8}
-------------------------

Several unresolved issues and unmet needs with regard to optimal DAPT duration after DES placement in clinical practice should be addressed from large-sized ongoing clinical trials. The previous, five randomized trials comprising nearly 10,000 patients indicated that extended courses of clopidogrel did not contribute favorably to patient outcomes and might in fact be detrimental in terms of safety outcomes. However, this conclusion would be too early to make a firm statement due to several limitations in terms of relatively small numbers of patients, a low rate of events, and shorter follow-up period. All of these trials adopted open-label designs and none of the trials have been evaluated systematically according to clinical and anatomic risk profiles. Therefore, much larger, blinded, randomized clinical trials would provide more confirmative answer to determine the optimal DAPT duration after DES implantation (Table [3](#Tab3){ref-type="table"}) \[[@CR32]--[@CR37]\].Table 3Ongoing trials on duration of dual antiplatelet therapyStudyTotal *N* (DES)Stent typesDAPT durationFollow-up duration (months)Primary endpointDAPT (NCT00977938) \[[@CR32]\]20,645BMS, DES12 vs. 30 m30All-cause death, MI or CVAISAR-SAFE (NCT00661206) \[[@CR33]\]6,000DES6 vs. 12 m15All-cause death, MI, ST, CVA or bleedingOTIDUAL (NCT00822536) \[[@CR34]\]3,120ZES3 vs. 12 m36Nonfatal MI, CVA or bleedingARCTIC (NCT00827411) \[[@CR35]\]2,500DES12 vs. \>12 m18--30All-cause death, MI, ST, CVA or urgent revascularizationEDUCATE (NCT01069003)2,500ZES12 vs. 30 m24--36Incidence of cardiac death, MI, ST, bleeding and DAPT complianceGLOBAL-LEADERS (NCT01813435)16,000Conventional DAPT 12 m vs. ticagrelor24All-cause death or MIISAR-CAUTION \[[@CR36]\]3,000DESAbrupt vs. tapered interruption3Cardiac death, MI, ST, CVA, bleeding or rehospitalization due to ACSSMART-DATE (NCT01701453)3,000New-generation DES6 vs. 12 m18All-cause death, MI, CVA, ST or bleedingSECURITY (NCT00944333)4,000Second generation DES6 vs. 12 m24Definite or probable ST between 6--24 mNIPPON (NCT01514227)4,598Biolimus A9 stent6 vs. 18 m18All-cause death, MI, CVA or bleedingREDUCE (NCT02118870)1,500Combo stent3 vs. 12 m12All-cause death, MI, CVA or bleedingDAPT-STEMI (NCT01459627)1,100DES6 vs. 12 m24All-cause death, MI, CVA, bleeding or any revascularization*BMS* bare-metal stents, *CVA* cerebrovascular accident, *DAPT* dual antiplatelet therapy, *DES* drug-eluting stents, *HR* hazard ratio, *MI* myocardial infarction, *PCI* percutaneous coronary intervention, *ST* stent thrombosis, *ZES* zotarolimus-eluting stent

In the largest scale study to date, the Dual Antiplatelet Therapy \[DAPT (NCT00977938)\] study enrolled more than 20,000 patients treated with any generation of DES and approximately 3,000 patients with BMSs to either 12 or 30 months of DAPT, with patients stratified according to clinical and angiographic complexity \[[@CR32]\]. Unlike the preceding randomized trials (except OPTIMIZE), study therapy was blinded and was masked. The primary results will be presented in the upcoming scientific meeting of the American Heart Association later this year. Another ongoing trial is The Safety And Efficacy of 6-month Dual Antiplatelet Therapy After Drug-Eluting Stenting \[ISAR-SAFE (NCT00661206)\], which evaluates a 6- or 12-month DAPT among 6,000 patients \[[@CR33]\]. And OPTImal DUAL antiplatelet therapy trial \[OPTIDUAL (NCT00822536)\] is ongoing to assess the efficacy and safety of 12 versus 48 months of DAPT after DES implantation \[[@CR34]\]. In the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting \[ARCTIC (NCT00827411)\] study, diverse durations of DAPT based on the platelet function monitoring is currently under investigation among 2,500 patients \[[@CR35]\].

Currently, an increasing number of patients are receiving the second-generation P2Y~12~ inhibitors (prasugrel or ticagrelor) instead of clopidogrel which demonstrate more potent suppression of platelet activity, leading to reduction of recurrent ischemic events \[[@CR37], [@CR38]\]. Based on these results, recent guidelines recommended prasugrel and ticagrelor on equal terms with clopidogrel in the patient with ACS or stent implantation \[[@CR13]\]. However, studies on optimal duration of DAPT with these newer drugs are still very limited. In the upcoming years, a variety of trials with unique combinations with newer P2Y~12~ inhibitors in a diverse duration could be suggested among patients who are undergoing PCI with DES implantation. The MEDTRONIC Endeavor Drug-Eluting Stenting: Understanding Care, Antiplatelet Agent and Thrombotic Events (EDUCATE, NCT01069003) study is designed to analyze 12 versus 30 months of DAPT; after 12 months of routine DAPT, patients will be randomly allocated to the placebo, clopidogrel or prasugrel group. In the clinical study comparing two forms of antiplatelet therapy after stent implantation trial \[GLOBAL LEADERS (NCT01813435)\], 1 month of ticagrelor plus aspirin followed by 23 months of ticagrelor monotherapy will be compared to 12 months of DAPT followed by aspirin monotherapy.

There was an also effort to figure out the optimal mode of DAPT discontinuation. The Abrupt Versus Tapered Interruption of Chronic Clopidogrel Therapy After DES Implantation \[ISAR-CAUTION (NCT00640679)\] study addressed the question of whether clopidogrel should be discontinued abruptly or with a progressive downgraded dosing \[[@CR36]\]. Patients with planned discontinuation of chronic clopidogrel therapy after DES implantation were randomized in a double-blinded fashion to either gradual discontinuation (according to a tapering schema over 4 weeks) or abrupt discontinuation (after continued clopidogrel therapy for additional 4 weeks) and followed for 3 months of the composite of cardiac death, MI, stroke, ST, major bleeding or rehospitalization. Initially, 3,000 patients planned to enroll but, the due to the slow recruitment, study was stopped prematurely after enrollment of 782 patients; at this point, tapered discontinuation of chronic clopidogrel therapy is not superior to abrupt discontinuation regarding the primary endpoint in this study.

As recent studies contain more data on the second-generation DES, clinicians are expecting that short duration of DAPT would be enough in the real world. But neither previous clinical studies nor ongoing randomized trials thus far have been designed to distinguish outcomes according to type of stents, several clinical risk profiles, lesions, and procedural complexities (i.e., ACS, diabetes mellitus, renal failure, low ejection fraction, multiple stents, long stents, left main stents, or bifurcation stents). Further larger trials with an enough statistical power to address this specific issue are required comprising all of these data to establish a firm policy for DAPT duration.

Conclusions {#Sec9}
===========

Dual antiplatelet therapy with aspirin and a P2Y~12~ inhibitor has significantly improved the outcomes of patients undergoing PCI. Because of the relative risk and benefit associated with the use of DESs and DAPT, defining the optimal duration of DAPT would be very critical in real practice. Although the latest PCI guidelines recommended at least 1 year of DAPT after DES placement, recent randomized clinical trials have demonstrated that a shorter duration of DAPT would be safe and effective than longer treatment, but these trials are still limited due to a few cardiovascular events, small-to-intermediate size of study, and inherent limitations of study designs. Upcoming results of much larger, double blind, and randomized clinical trials, with a higher use of second- and newer generation DESs will guide the physician in making informed decisions on the optimal duration of DAPT for patients receiving DES implantation. In addition, more data would be required to define the role of newer generation P2Y~12~ inhibitors, including ticagrelor and prasugrel, for diverse clinical settings.
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